How Is TB Transmitted? Sébastien Gagneux, PhD 20 th March, 2008

Similar documents
XDR and MDR TB Urgent Research Priorities. Gerald Friedland MD Yale School of Medicine Nelson R Mandela School of Medicine

XDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps

What can be done against XDR-TB?

Drug resistance TB in People Living with HIV: research questions and priorities.

The WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps

3.1 PHASE 2 OF THE GLOBAL PROJECT

The epidemiology of tuberculosis

Drug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye

Transmissibility, virulence and fitness of resistant strains of M. tuberculosis. CHIANG Chen-Yuan MD, MPH, DrPhilos

Molecular Epidemiology of Tuberculosis. Kathy DeRiemer, PhD, MPH School of Medicine University of California, Davis

2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges

A ten-year evolution of a multidrugresistant tuberculosis (MDR-TB) outbreak in an HIV-negative context, Tunisia ( )

511,000 (57% new cases) ~50,000 ~30,000

Drug-resistant Tuberculosis

Drug-resistant Tuberculosis

Name of the presenter

Pandemic H1N Dr. Maria Neira Global Influenza Programme WHO, Geneva

A Review of the Sutezolid (PNU ) Patent Landscape

Global, National, Regional

Global, National, Regional

C R E A E. Consortium to Respond Effectively to the AIDS-TB Epidemic. An International Research Partnership

CANCER FACT SHEETS: BREAST CANCER

Recommended composition of influenza virus vaccines for use in the 2007 influenza season

Main developments in past 24 hours

MARKET NEWS for pig meat

Current Situation on Avian Influenza and the pandemic threat

Recommended composition of influenza virus vaccines for use in the influenza season

4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB

Controlling TB in the era of HIV

The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific

Multidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017

Access to treatment and disease burden

WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA

TB, BCG and other things. Chris Conlon Infectious Diseases Oxford

The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific

CANCER FACT SHEETS: LIVER CANCER

OUT-TB Web. Ontario Universal Typing of Tuberculosis: Surveillance and Communication System

OIE Situation Report for Highly Pathogenic Avian Influenza

Undetectable = Untransmittable. Mariah Wilberg Communications Specialist

RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE WINTER SEASON

CANCER FACT SHEETS: ALL CANCERS EXCLUDING NON-MELANOMA SKIN CANCER

Epidemiology of Hepatitis B in sub-saharan Africa. 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur

OIE Situation Report for Highly Pathogenic Avian Influenza

Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA

EU Market Situation for Poultry. Committee for the Common Organisation of the Agricultural Markets 20 April 2017

Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics

CANCER FACT SHEETS: STOMACH CANCER

OIE Situation Report for Avian Influenza

Terms and Conditions. VISA Global Customer Assistance Services

Qian Gao Fudan University

Estimating the global burden of tuberculosis. WHO estimates of TB incidence, prevalence and mortality, by country,

Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA

Global progress in vaccine development

Cotton Trade 02/03 03/04 04/05 05/06 06/07 07/08 08/09 09/10 10/11 11/12 12/13

Diagnosis of drug resistant TB

Influenza Update N 176

Multidrug-resistant Tuberculosis - World, Europe, Switzerland

HPAI H5(N8) in Member States in poultry, captive and wild birds

HIV and Harm Reduction in Prisons

Sperm donation Oocyte donation. Hong Kong þ Guideline þ þ Hungary þ þ þ þ Israel þ þ þ þ Italy þ þ þ. Germany þ þ þ þ Greece þ þ þ þ

Need for Chronic Viral Hepatitis Monitoring System

Copyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved ISBN

Molecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research

OIE Situation Report for Avian Influenza

Influenza Update N 157

2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services:

TB trends and TB genotyping

GLOBAL AND REGIONAL SITUATION OF AVIAN INFLUENZA

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

OIE Situation Report for Avian Influenza

Key issues for HIV testing and

WELLNESS COACHING. Wellness & Personal Fitness Solution Providers

Pharmaceutical, Medical and Health-related Government and Regulatory bodies around the world.

Global EHS Resource Center

West Nile Disease. World situation and impact on public health

Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013

Seizures of ATS (excluding ecstasy ), 2010

MARKET NEWS for pig meat

The Coming Crisis in Antibiotics. Ramanan Laxminarayan European Parliament Conference June 2017

#4 (Tuberculosis OR TB OR Pulmonary Tuberculosis OR Multi-Drug Resistant Tuberculosis OR MDR OR Extremely-Drug Resistant Tuberculosis or XDR)

OIE Situation Report for Highly Pathogenic Avian Influenza

Pandemic Risk Modeling

Global Rotavirus Surveillance Network

Drug Prices Report Opioids Retail and wholesale prices * and purity levels,by drug, region and country or territory (prices expressed in US$ )

MDR-TB and HIV co-infection in Eastern Europe. Francis Drobniewski MBBS PhD Professor of Global Health and Tuberculosis

The State of Measles and Rubella in the WHO European Region

Appendix F: Test-Curriculum Matching Analysis

Current State of Global HIV Care Continua. Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2

CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...

Hepatitis B vaccination worldwide: Lessons learnt and the way forward

NDI HUMPHREY NGALA, PHD UNIVERSITY OF YAOUNDE I ENS, DEPT OF GEOGRAPHY TEL: /

Progress on the targets of Millennium Development Goal 6 in central and eastern Europe and central Asia

Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG-SAFE)

Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB

Transmission of MDR/XDR Tuberculosis in Shanghai. Qian Gao Shanghai Medical College Fudan University

Agricultural Outlook Forum Presented: February 16, 2006 THE CURRENT STATE OF SCIENCE ON AVIAN INFLUENZA

with these FACTS... 2

Asia: Portrait of a Changing Region

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

CYCLOTRONS WORLD MARKET REPORT & DIRECTORY EDITION TOC and Summary USED IN NUCLEAR MEDICINE MARKET DATA, COMPANIES PROFILES.

Transcription:

How Is TB Transmitted? Sébastien Gagneux, PhD 20 th March, 2008

Today s Outline 1) Global spread of Mtb Comparative genomics Phylogeny 2) Transmission of drug-resistant Mtb Fitness assays Molecular epidemiology

The Global Diversity of Mtb Global strain collection: 875 strains 80 countries TbD1 12 can 239 105 207 M. canettii Indo-Oceanic 181 East-Asian 9 150 142 750 East-African-Indian 122 Middle East 115 182 183 193 Americas Europe Large Sequence Polymorphisms pks 15/1 Δ7bp 219 H37Rv-like 174 726 West Africa Euro-American 761 South Africa 724 Central Africa 711 West-African-1 702 West-African-2 7, 8, 10 M. bovis lineage Gagneux et al. PNAS 2006

Geographic Distribution of Mtb Diversity Gagneux et al. PNAS 2006

Global TB Burden by Mtb Lineage Estimated number of prevalent cases in 2003 (WHO 2005) 6 5 4 3 Whole-genome sequences: H37Rv (Sanger) CDC1551 (TIGR) F11 (Broad) C (Broad) Haarlem (Broad) 210 (TIGR) 2 1 0 E & SE -Asia Indian sub-continent Sub-Saharan Africa C-Asia / Russia Americas Europe N-Africa Middle East Gagneux & Small Lancet ID 2007 Number of cases (millions)

Modern MTB Ancient MTB Global Phylogeny of M. tuberculosis 108 strains ~70kbp/strain 100 100 100 100 Animal adapted M. canettii 5 Gagneux et al. in preparation

Out-of-Africa of M. tuberculosis?

1) Global Spread of Mtb: Conclusions Origin of Mtb most likely in Africa Geographical distribution of Mtb diversity suggests Out-of-Africa But! More recent migration also involved (travel, trade, conquest) Different evolutionary histories might have resulted in lineage-specific phenotypic differences (vaccines!).

Where Is TB Now? Global TB 2005 Estimates All forms of TB MDR-TB Estimated number of cases 8.8 million 424,000 Estimated number of deaths 1.6 million 116,000 XDR-TB 27,000 16,000 >50% Mortality Entering post-antibiotic era!

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. WHO 2005. All rights reserved Countries with confirmed XDR-TB Argentina Armenia Bangladesh Brazil Canada Chile China, Hong Kong SAR Czech Republic Ecuador France Portugal Georgia Republic of Korea Germany Russian Federation Islamic Republic of Iran Italy South Africa Japan Spain Latvia Sweden Mexico Thailand Norway Based on information provided to WHO Stop TB Department March 2007 UK Peru USA

XDR-TB in the

2) Transmission of Drug-resistant Mtb Public Health is important What about Biology? Is drug-resistance costly (to the bug)? Studies in E. coli suggest fitness cost MDR / XDR-TB associated with HIV Are XDR strains less fit?

Fitness: The Experimental Approach RIF S RIF R Conditioning Competition no RIF CFU measurements @ baseline & endpoint RIF

1 st strain background: CDC1551 CDC1551 RIF R mutants 200ul wildtype RIF 2 nd strain background: T85/Beijing T85 RIF R mutants 200ul wildtype RIF

Clinical Isolates with Acquired RIF R 4 to 37 months RIF S RIF R Same DNA fingerprint

Fitness Cost of Rifampicin-Resistant Mtb Lab-derived mutants: Mean relative fitness 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 S531L H526Y H526D S531W H526R S522L Q513L H526P R529Q rpob mutation Clinical strains: Mean relative fitness 1.3 1.2 1.1 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 1 2 3 4 5 6 7 8 9 10 S531L Isolate pair other rpob Gagneux et al. Science 2006

Clinical Frequency of rpob Mutations rpob mutation S531L H526Y H526D S531W H526R R529Q Mean fitness 1.02 0.82 0.78 0.82 0.82 0.58 Clinical frequency (%)* 54 11 7 4 3 0 * based on 840 clinical isolates (O Sullivan et al. 2005)

Fitness: The Molecular Epidemiology Approach DNA fingerprinting (IS6110 RFLP) reactivated transmitted

Population-based Molecular Epidemiological Study in San Francisco INH resistance caused by different mutations Different INH R mutations have different effects on bacterial virulence / fitness in animal models katg activates INH and is important for virulence Hypothesis: Mutants with high fitness cost will transmit less

Mutations in 152 INH R Isolates from SF (1991-1999) Mutation N (%) KatG activity 1) Non-functional KatG 34 (22.4) -- 2) katg S315T 62 (40.8) -+ 3) inha prom. -15 c t 39 (25.7) + + No mutation 17 (11.1) + + Gagneux et al. PLoS Pathogens 2006

INH R Mutation and RFLP Clustering Mutation KatG activity % RFLP clustering p-value 1) Non-functional KatG -- 0.0 reference 2) katg S315T -+ 11.3 < 0.05 3) inha -15 c t + + 17.8 < 0.01

The Biogeography of Mtb 12 can M. canettii 239 Indo-Oceanic TbD1 105 207 181 East-Asian 9 150 142 750 East-African-Indian 122 Middle East 115 182 183 193 Americas Europe pks 15/1 Δ7bp 219 H37Rv-like 174 West Africa Euro-American 726 761 South Africa 724 Central Africa 711 West-African-1 702 West-African-2 7, 8, 10 M. bovis lineage Gagneux et al. PNAS 2006

Does Strain Lineage Impact Propensity Towards Low / High-Cost INH R Mutations? Lineage / Mutation Blue Lineage: 1) Non-functional katg mutations Red Lineage: 2) katg S315T Pink Lineage: 3) inha prom. -15 c t Odds Ratio 5.6 2.0 3.8 P-value < 0.001 0.052 < 0.001

Blue Mtb (Beijing) Associated with MDR The Russia Gambia The Vietnam Gambia The South Gambia Africa

2) Transmission of Drug-resistant Mtb: Conclusions Fitness and transmission of drug-resistant Mtb is a function of: Specific mutation Strain genetic background Compensatory evolution (?) Implications for predicting the future of MDR / XDR-TB

Evolution of Drug Resistance No-cost mutation Pre-adapted genetic background Fitness DS DR DR DR Compensation Time

Acknowledgments ISB, Seattle Peter Small Hadar Sheffer Lee Rowen Jared Roach Marta Janer Scott Bloom NIMR, London Douglas Young Vivek Rao Damien Portevin Stanford Marcus Feldman Misha Lipatov Dmitri Petrov Ruth Hershberg Brendan Bohannan Alex Pym Clara Davis Long Gary Schoolnik Tran Van Funding: UC San Francisco Phil Hopewell Midori Kato-Maeda Swiss National Science Foundation Novartis Foundation National Institutes of Health Wellcome Trust